

Title (en)

RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Title (de)

RNA-INTERFERENZ-VERMITTELTE HEMMUNG DER EXPRESSION DER GENE FÜR DIE TNF- UND TNF-REZEPTOR-SUPERFAMILIEN UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID)

Title (fr)

INHIBITION, INDUITE PAR ARN D'INTERFERENCE, DE L'EXPRESSION GENIQUE DE LA SUPERFAMILLE TFN ET DE LA SUPERFAMILLE DES RECEPTEURS DE TFN A L'AIDE D'UN ACIDE NUCLEIQUE A INTERFERENCE COURTE (SINA)

Publication

**EP 1478730 A2 20041124 (EN)**

Application

**EP 03713502 A 20030220**

Priority

- US 0304741 W 20030220
- US 35858002 P 20020220
- US 36312402 P 20020311
- US 38678202 P 20020606
- US 40678402 P 20020829
- US 40837802 P 20020905
- US 40929302 P 20020909
- US 42935902 P 20021126
- US 44012903 P 20030115

Abstract (en)

[origin: WO03070897A2] The present invention concerns methods and reagents useful in modulating TNF superfamily and TNF receptor superfamily gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against TNF superfamily and TNF receptor superfamily gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of septic shock, rheumatoid arthritis, HIV and AIDS, psoriasis, inflammatory or autoimmune disorders and any other disease or condition that responds to modulation of TNF and/or TNF receptor expression or activity.

IPC 1-7

**C07H 21/04**; **A61K 48/00**; **C12N 15/00**

IPC 8 full level

**C12N 15/09** (2006.01); **A61K 48/00** (2006.01); **A61P 9/00** (2006.01); **A61P 17/06** (2006.01); **A61P 29/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/18** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C12N 15/113** (2010.01); **A61K 38/00** (2006.01)

CPC (source: EP)

**A61P 9/00** (2017.12); **A61P 17/06** (2017.12); **A61P 29/00** (2017.12); **A61P 31/04** (2017.12); **A61P 31/18** (2017.12); **A61P 37/06** (2017.12); **A61P 43/00** (2017.12); **C12N 15/1136** (2013.01); **C12N 15/1138** (2013.01); **C12N 2310/111** (2013.01); **C12N 2310/14** (2013.01); **C12N 2310/315** (2013.01); **C12N 2310/317** (2013.01); **C12N 2310/318** (2013.01); **C12N 2310/321** (2013.01); **C12N 2310/322** (2013.01); **C12N 2310/332** (2013.01); **C12N 2310/53** (2013.01)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

DOCDB simple family (publication)

**WO 03070897 A2 20030828**; **WO 03070897 A3 20040910**; AU 2003217550 A1 20030909; CA 2477014 A1 20030828; EP 1478730 A2 20041124; EP 1478730 A4 20060125; JP 2005517433 A 20050616

DOCDB simple family (application)

**US 0304741 W 20030220**; AU 2003217550 A 20030220; CA 2477014 A 20030220; EP 03713502 A 20030220; JP 2003569790 A 20030220